Carbamate-Linked Hydroxamic Acid Derivatives for HDAC Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hydroxamic acid derivatives for inhibiting histone deacetylase (HDAC) have limitations in terms of potency and bioavailability, necessitating the development of new compounds with improved properties for treating cellular proliferative diseases such as cancer, autoimmune, allergic, and inflammatory diseases, as well as neurodegenerative disorders and restenosis.
Innovation Solution
Development of hydroxamic acid derivatives with a carbamate linkage that serve as potent HDAC inhibitors, specifically designed to target HDAC enzymes, thereby regulating gene expression and inducing cell differentiation, growth arrest, or apoptosis in neoplastic cells, while minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current hydroxamic acid derivatives are used to inhibit HDAC, then HDAC inhibition activity is achieved, but potency and bioavailability are limited
Solution Approach 1:
The patent modifies the chemical structure of hydroxamic acid derivatives by introducing a carbamate linkage at the R1 position, changing physical and chemical parameters such as molecular weight, lipophilicity, and metabolic stability. These parameter changes improve both potency (lower IC50 values) and bioavailability while maintaining HDAC inhibition activity
Solution Approach 2:
The invention creates composite molecular structures by combining hydroxamic acid moieties with carbamate linkages and various substituent groups (aryl, heteroaryl, alkyl). This composite approach allows optimization of pharmacokinetic properties and pharmacodynamic activity simultaneously, resolving the contradiction between maintaining inhibition activity and improving potency/bioavailability
2Reliability
If HDAC inhibition is increased to treat cancer, then transcriptional repression of tumor suppressor genes is enhanced, but toxicity may increase
Solution Approach 1:
The patent introduces specific substituent patterns at different positions (R1, R2, R3, R4) of the hydroxamic acid derivative structure, creating local variations in chemical properties. This allows selective enhancement of HDAC inhibition at the target site while minimizing off-target effects and toxicity through localized molecular modifications
Solution Approach 2:
The carbamate linkage introduces metabolic lability into the molecule, allowing controlled breakdown after therapeutic action. This disposable approach enables the drug to perform its transcriptional repression function effectively while being metabolized to non-toxic products, reducing cumulative toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new hydroxamic acid derivatives effectively inhibit HDAC activity, leading to increased transcription of specific genes, such as p21, and induce terminal differentiation or apoptosis in cancer cells, offering improved therapeutic efficacy with potentially reduced side effects.
Implementation Method 1
compounds having a hydroxamic acid moiety have been shown to inhibit histone deacetylases (HDACs), based at least in part on the zinc binding property of the hydroxamic acid group
Data Source
AI summary
The invention relates to hydroxamic acid derivatives having carbamate linkage with the structural formulathat are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous systems (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.